The transaction adds C2’s growing livestreaming business to Creatd’s AI and creator driven tech portfolio while furthering Creatd’s national exchange uplisting strategy

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — Creatd, Inc. (OTCQB: CRTD) today announced that it has acquired a 10% equity stake in C2 Capital Group, Inc., operator of the live-streaming platform C2 Live, and has additionally signed a non-binding letter of intent to acquire the remaining equity of the company.

This investment is part of Creatd’s strategy to grow its portfolio of creator-driven platforms, leveraging the communities it has already fostered through the Vocal platform, as well as C2 Live’s audience of over 1.5 million.

Creatd expects the initial 10% investment to add approximately $3.6 million to its current shareholders’ net equity of nearly $5 million. As a result, the Company expects to report about $8 million in total stockholders’ net equity in its third quarter financials. Creatd will be completing the required due diligence in order to purchase the remaining 90% of C2 Live in the fourth quarter of 2026.

“Creatd has a clean capital structure, a solid cash position, increasing net equity, a scalable operating model and, as of Friday, September 25th, an effective S-1 that creates over $15 million of market value of unrestricted publicly-held shares,” said Jeremy Frommer, Creatd’s CEO. “The C2 transaction would add a synergistic livestreaming business to our growing AI and creator platform capabilities. We look forward to completing the purchase of the remaining equity of C2 Live during the fourth quarter of 2026.”

“Creatd brings complementary technology, creator-platform and public-company experience to C2 Live,” said Lamont Wilcott, C2 Live’s CEO. “Together with Creatd we will improve the app, add new features, support more creators and viewers, and build on the growth we have achieved since launch. The minority investment gives both companies a practical way to work together as we complete diligence and evaluate the proposed acquisition of the remaining equity.”

About Creatd, Inc.
Creatd, Inc. (OTCQB: CRTD) is a company focused on technology and AI-enabled businesses, digital media properties, and intellectual property assets. Through its operating subsidiaries and strategic investments, the Company develops and supports opportunities for creators, entrepreneurs, and emerging growth initiatives.

About C2 Capital Group
C2 Capital Group operates C2 Live, a livestreaming platform that helps creators connect with audiences in real time through interactive and gamified experiences. Launched in August 2024, C2 Live supports creator monetization through virtual gifting and in-app features designed to encourage community participation and engagement. C2 Live also integrates AI-enabled features that expand how creators engage, grow, and monetize their audiences.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations, estimates, and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Creatd undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Contact:
ir@creatd.com

RUTLAND, Vt., Sept. 29, 2026 (GLOBE NEWSWIRE) — Casella Waste Systems, Inc. (Nasdaq: CWST), a regional solid waste, recycling and resource management services company, announced that the New York State Department of Environmental Conservation issued a permit to expand its Hakes Construction and Demolition (“C&D”) Landfill located in Campbell, New York (“the Hakes Landfill”) disposal area by approximately 43.3 acres. The expansion provides an estimated 5.8 million cubic yards of additional disposal capacity.

The Hakes Landfill is currently permitted to accept up to 466,000 tons per year of C&D material.

“We are pleased to receive this expansion permit at our Hakes facility,” said Ned Coletta, President and CEO of Casella Waste Systems, Inc. “Reliable C&D disposal capacity is a critical component of New York State’s solid waste infrastructure, and we take pride in providing service that we believe supports the opportunity for broader regional economic growth. This expansion positions us to serve that demand while preserving valuable capacity across our municipal solid waste landfill network.”

“With this expansion combined with the current permitted airspace at the site, we expect to have approximately 20 years of capacity at current run-rates,” Coletta said.

The project also adds 21.7 acres to the existing on-site soil borrow area from which soils are excavated for landfill construction and operation. Further, this provides the opportunity for the Company to relocate and construct new infrastructure including leachate transfer and storage and gas collection and treatment systems.

About Casella Waste Systems, Inc.
Casella Waste Systems, Inc., headquartered in Rutland, Vermont, provides resource management expertise and services to residential, commercial, municipal, institutional and industrial customers, primarily in the areas of solid waste collection and disposal, transfer, recycling and organics services in the eastern United States. For more information, visit www.casella.com.

Safe Harbor Statement
Certain matters discussed in this press release, including, but not limited to, the statements regarding the estimated additional disposal capacity of the Hakes Landfill and the plans for new infrastructure at the landfill, are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified as such by the context of the statements, including words such as “believe,” “expect,” “anticipate,” “plan,” “may,” “would,” “intend,” “estimate,” “projects,” “will,” “guidance” and other similar expressions, whether in the negative or affirmative. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management’s beliefs and assumptions. The Company cannot guarantee that it will achieve the financial results, plans, intentions, expectations or guidance disclosed in the forward-looking statements made. Such forward-looking statements, and all phases of our operations, involve a number of risks and uncertainties, any one or more of which could cause actual results to differ materially from those described in our forward-looking statements. Such forward-looking statements, and all phases of the Company’s operations, involve a number of risks and uncertainties, any one or more of which could cause actual results to differ materially from those described in its forward-looking statements. Such risks and uncertainties include or relate to, among other things: any potential appeal of the Hakes C&D Landfill permit described above or the Company may not fully recognize the expected benefits from such permit.

There are a number of other important risks and uncertainties that could cause the Company’s actual results to differ materially from those indicated by such forward-looking statements. These additional risks and uncertainties include, without limitation, those detailed in Item 1A. “Risk Factors” in the Company’s most recently filed Form 10-K and in other filings that the Company may make with the Securities and Exchange Commission in the future.

The Company undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations
Henry Baby, CFA
Vice President of Investor Relations and Finance
(802) 417-3841

Media Relations
Jeff Weld
Vice President of Communications
(802) 772-2234

AB Amber Grid, legal entity code 303090867, registered address: Laisvės Ave. 10, LT-04215 Vilnius, Lithuania.

At the Extraordinary General Meeting of Shareholders of AB Amber Grid held on 29 September 2026, the following resolutions were adopted:

1. Approval of the new wording of the Articles of Association of AB Amber Grid

1.1. To approve the new wording of the Articles of Association of AB Amber Grid (attached).

1.2. To authorize the Chief Executive Officer of AB Amber Grid (with the right to sub-authorize) to sign the amended Articles of Association and register them with the Register of Legal Entities of the Republic of Lithuania in accordance with the procedure established by legal acts, to submit and collect documents, and to perform all other actions necessary for the implementation of this resolution of the Extraordinary General Meeting of Shareholders.

2. Election of a Member of the Board

2.1. To elect Ms Ina Medvedeva-Ragėnienė as a member of the Board of AB Amber Grid, a civil servant responsible for the area of competence covering oversight of the implementation of the National Energy Independence Strategy and national security interests, for the period from the date of adoption of this resolution by the Extraordinary General Meeting of Shareholders until the expiry of the current term of office of the Board of AB Amber Grid.

2.2. To authorize the Chief Executive Officer of AB Amber Grid, no later than within 5 (five) business days from the date of adoption of this resolution, to sign on behalf of AB Amber Grid with the newly elected Board member the standard agreement regarding the activities of a member of the Board of AB Amber Grid, approved by Resolution No. 1 of the Ordinary General Meeting of Shareholders of AB Amber Grid held on 30 April 2024.

2.3. To authorize the Chief Executive Officer of AB Amber Grid (with the right to sub-authorize) to notify the Register of Legal Entities of the Republic of Lithuania of the election of the Board member, register the amended data with the Register of Legal Entities of the Republic of Lithuania, and perform all other related actions.

Attachments:

  1. Articles of Association of AB Amber Grid
  2. Press Release 

For more information:

Eglė Krasauskienė
Head of Communications
AB Amber Grid
+370 637 06011
e.krasauskiene@ambergrid.lt

Attachments

Ahead of Black Friday and Cyber Monday, a new survey from Sezzle and Morning Consult finds checkout flexibility is closely linked to whether shoppers complete a purchase or abandon their cart.

Minneapolis, MN, Sept. 29, 2026 (GLOBE NEWSWIRE) — Sezzle, a leader in flexible payments, today released new survey findings that carry a clear message for retailers heading into Black Friday and Cyber Monday: offering the right payment option at checkout can be the difference between a completed sale and an abandoned cart.

The survey, conducted in partnership with Morning Consult, found that 66% of shoppers said they were likely to abandon a purchase entirely if their preferred Buy Now, Pay Later option wasn’t available at checkout. More than half, 57%, say they always or often compare payment options before they even start shopping, meaning the decision to buy is often made before a shopper ever reaches the cart.

“Retailers spend all year building toward this shopping season,” said Paul Paradis, President and co-founder of Sezzle. “The last thing they want is to lose a sale at the final step because checkout didn’t offer the payment option a shopper needed. If it isn’t there, the cart just gets abandoned, and the shopper will often not come back to try again.”

The stakes are especially high with Gen Z, a generation that already shops around for payment options more than any other. 85% of Gen Z BNPL shoppers have used more than one provider, and they use BNPL more often than any other generation, with 72% using the tool two or more times a month, compared with 27% of Boomers. Retailers who offer only one BNPL option risk losing this audience to a competitor who offers the one they actually use.

The findings echo a pattern retailers have seen before. Merchants once routinely refused American Express over its higher fees, but by the end of 2019, 99% of U.S. merchants that already accepted credit cards accepted Amex as well.² In Sezzle’s view, that shift reflects a simple trade-off: the cost of turning away a customer’s preferred payment method eventually outweighed the cost of accepting it. Buy Now, Pay Later may be heading down the same road: more than a third of shoppers surveyed say they’ve been declined by a BNPL service before.

For a retailer offering only one BNPL option, a decline isn’t just a lost approval — it can be a lost sale entirely. Sezzle approves more than 90% of applicants¹, making it a provider retailers can add specifically to capture the shoppers other options turn away. Offering more than one provider gives retailers a second shot at that same sale. And the upside isn’t small: 82% say BNPL has let them make a purchase they would have otherwise postponed or skipped altogether, meaning the option at checkout can be the deciding factor in whether a sale happens at all.

Want to reach more shoppers ahead of the holiday season? See how Sezzle can help.

¹ Based on Sezzle internal data; reflects the percentage of unique applicants approved, YTD 2026.

² Source: CNBC Select, “99% of merchants in the U.S. who accept credit cards now take American Express,” citing The Nilson Report (data as of year-end 2019). https://www.cnbc.com/select/american-express-merchant-acceptance/

Methodology: Survey conducted by Morning Consult on behalf of Sezzle from July 29 to August 5, 2026, among 2,090 U.S. general population adults. Of these, 1,245 respondents meet a Federal Reserve-based paycheck-to-paycheck definition; findings on cart abandonment, BNPL declines, and postponed purchases are based on the subset of that group who have used a BNPL service (n=388). Generational comparisons on BNPL usage frequency (Gen Z vs. Baby Boomers) are drawn from a separate sample of past-12-month BNPL users (n=223 Gen Z, n=186 Baby Boomers). Results are weighted to be nationally representative within each sample.

About Sezzle Inc.

Sezzle is a forward-thinking fintech company committed to financially empowering the next generation. Designed to support users throughout every stage of their financial journey, Sezzle’s all-in-one app enables users to shop, earn, and learn in a seamless experience. By offering point-of-sale financing and digital payment services, Sezzle enhances purchasing power while connecting millions of consumers with its global network of merchants. Centered on transparency, inclusivity, and ease of use, Sezzle empowers consumers to manage spending responsibly and build lasting financial independence.

For additional assets and news on Sezzle please visit https://sezzle.com/news/. 

Follow Sezzle on social media: LinkedIn | Instagram | X 

Sezzle Media Contact:

Erin Foran

Tel: (651) 403-2184

Email: erin.foran@sezzle.com

Attachment

CONTACT: Erin Foran
Sezzle
6514032184
erin.foran@sezzle.com

FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule.

As previously disclosed, on January 15, 2026 the Company received a notice from Nasdaq indicating that the closing bid price of the Company’s common stock had been below $1.00 for 30 consecutive business days, and, consequently, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the applicable minimum bid price requirement for The Nasdaq Global Market).

Following an appeal and hearing before the Nasdaq Hearings Panel, the Panel determined to transfer the Company to The Nasdaq Capital Market effective August 4, 2026 and granted the Company an extension to demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) (the applicable minimum bid price requirement for The Nasdaq Capital Market) (the “Bid Price Rule”) by September 3, 2026.

At the close of trading on August 20, 2026, the Company effected a 1-for-50 reverse stock split.

On September 24, 2026, the Company received a notice from Nasdaq stating that, for the 13 consecutive trading days from August 21, 2026 to September 9, 2026, the closing bid price of the Company’s common stock had been above $1.00 per share. Accordingly, Nasdaq determined that the Company has regained compliance with the Bid Price Rule, and the matter is now closed.

About Liminatus

Liminatus Pharma, Inc. (Nasdaq: LIMN) is a biotechnology company developing innovative immuno-oncology and cell therapy candidates. The Company’s portfolio includes IBA101, a next-generation anti-CD47 monoclonal antibody, as well as oncology-focused cellular therapy programs including IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. Liminatus is focused on advancing differentiated therapeutic approaches designed to address unmet needs in cancer treatment.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the applicable federal securities laws. All statements that are not statements of historical fact are forward-looking statements. Forward-looking statements may be identified by the use of words such as “may,” “could,” “would,” “should,” “predict,” “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” or other similar expressions that predict or indicate future events or that are not statements of historical matter. These statements are based on assumptions and on the current expectations of the Company’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of Liminatus. These forward-looking statements are subject to a number of risks and uncertainties, including: (i) changes in business, market, financial, political and legal conditions; (ii) the Company’s continued ability to implement business plans; (iii) the risk of downturns, new entrants and a changing regulatory landscape in a highly competitive industry in which the Company operates; (iv) the Company’s continued listing on Nasdaq; and (v) those risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond the Company’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. The forward-looking statements contained in this press release speak only as of the date of this press release and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.

For more information, please contact:

Liminatus Pharma, Inc.
Chris Kim, CEO
info@liminatuspharma.com 
(213) 273-5453

Partnership Integrates Usio’s Embedded Payment Capabilities into Harris’ Utility CIS Platform

Utilities Gain Access to Modern, Flexible Payment Options Across Virtually All Payment Channels

SAN ANTONIO, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) — Usio, Inc. (“Usio” or the “Company”) (Nasdaq: USIO), a leading FinTech company that operates a full stack of integrated, cloud-based electronic payment and embedded financial solutions, today announced a strategic partnership with Harris Computer Corporation (Harris), a globally recognized provider of advanced enterprise software solutions, including billing and customer information systems for the utility industry.

Under the agreement, Harris has designated Usio as a ‘Preferred Payments Services Provider’ and will integrate Usio’s payment technology into its utility customer information system (CIS) platform. Utilities implementing Harris’s payment module will have their payment processing powered by Usio, enabling them to offer consumers a complete range of payment options, including credit and debit cards, ACH, and pinless debit. In addition, Usio will provide Harris’ customers with physical check and statement printing and distribution, prepaid card escheatment services, and other payment capabilities.

By embedding Usio’s comprehensive suite of payment solutions into their CIS technology, utility customers can integrate billing and payments through a single technology solution. Consumers increasingly expect secure, convenient, and flexible payment options, and this partnership assures utilities meet those expectations.

Harris has earned a strong global reputation for delivering solutions that help utilities improve operational efficiency, manage critical resources, and enhance customer service. By integrating Usio’s payment technologies into its platform, Harris further strengthens its ability to deliver a seamless, end-to-end customer experience that enhances the value of its CIS solution.

Louis Hoch, President and Chief Executive Officer of Usio, said, “We’re excited to partner with Harris to bring our embedded payment capabilities to the utility industry’s leading customer information platforms. Together, we’re enabling utilities to deliver a modern, flexible payment experience while simplifying the way they manage payment acceptance and disbursements. Harris is a leader in helping utilities operate more efficiently, and we’re honored that they’ve chosen our technology to continue to build on their reputation for innovative and creative solutions that meet the needs of today’s consumer.”

Dana Lendorf-McCarthy, Group President, Utilities and Telecom, Harris, added, “We are pleased to partner with Usio to provide utility organizations with integrated payment capabilities within our software solutions. As utilities continue to navigate evolving customer expectations and operational requirements, it is important that we offer flexible options that help streamline the payment experience. This partnership supports our ongoing commitment to delivering practical solutions that help our customers operate efficiently and serve their communities effectively.”

This agreement establishes a foundation for continued collaboration and innovation. Usio will support Harris’s implementation and go-to-market efforts, helping utility providers modernize the way they accept and manage payments.   Harris serves over 70,000 utility providers across the United States, making this partnership an excellent opportunity to accelerate the adoption of integrated payment technologies throughout the industry.

About Harris Computer Corporation (Harris)

Harris acquires vertical market software businesses, manages them using industry best practices, and builds them for the future. Through acquisitions, Harris has grown extensively from its roots in the utilities, local government, education, and healthcare sectors to operate over 250 businesses globally across more than twenty industries. Harris is an operating group of Constellation Software Inc. (TSX: CSU), one of North America’s most active acquirers of software businesses. To learn more, visit www.harrisutilities.com.

About Usio, Inc.

Usio, Inc. (Nasdaq: USIO), a leading, cloud-based, integrated FinTech electronic payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus, integrated software vendors and card issuers. The Company operates credit, debit/prepaid, and ACH payment processing platforms to deliver convenient, world-class payment solutions and services to clients through its unique payment facilitation platform as a service. The Company, through its Usio Output Solutions division, offers services relating to electronic bill presentment, document composition, document decomposition and printing and mailing services. The strength of the Company lies in its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the card issuing sector.

Usio is headquartered in San Antonio, Texas, and has offices in Austin, Texas. Websites: www.usio.com and www.akimbocard.com. 

Find us on LinkedIn, Facebook® and Twitter.

FORWARD-LOOKING STATEMENTS DISCLAIMER

Except for the historical information contained herein, this release contains forward-looking statements that are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding management’s intentions, beliefs, expectations, and strategies for the future, including statements regarding the Company’s operating and growth strategies. Forward-looking statements can be identified by words such as “believe,” “intend,” “look forward,” “anticipate,” “schedule,” “expect,” and similar expressions.

These forward-looking statements are subject to risks and uncertainties inherent in the Company’s business that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, among others, risk relating to economic conditions; the realization of anticipated benefits from the PostCredit acquisition; the Company’s ability to manage growth; the loss of key resellers; relationships with the Automated Clearing House network, bank sponsors, third-party card processing providers, and merchants; the security of the Company’s software, hardware, and information systems; volatility in the Company’s stock price; the need for additional financing; risks associated with new tax legislation; and compliance with complex federal, state, and local laws and regulations, as well as other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

One or more of these factors have affected, and in the future, could affect, the Company’s businesses and financial results and could cause actual results to differ materially from management’s plans and projections. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, undue reliance should not be placed on such statements which speak as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Contact:

Usio Investor Relations
ir@usio.com
210-249-4055

September Revenue Booked Through September 28 Approaches Twice August Levels, with Distributor Partnerships Now Spanning Six Key U.S. Markets

SANTA MARIA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — AMASS Brands Group (NASDAQ: AMSS) (“AMASS” or “the Company”), a premium, multi-category beverage platform spanning non-alcohol, functional, and alcohol 2.0 products, today announced that AMASS Electrolytes has achieved an approximately $1.4 million annualized revenue run rate following the line’s May 2026 launch. September revenue from its sparkling electrolyte mixers and hydration powders totaled approximately $116,000 through September 28, up 89% from August and more than triple June’s revenue, the line’s first full month of sales.

Since its debut, AMASS Electrolytes has established distributor partnerships across six key U.S. markets: California, Colorado, Georgia, Illinois, Michigan and New York. The business combines wholesale distribution of sparkling electrolyte mixers with a direct-to-consumer business in hydration powders.

“Electrolytes have moved out of the sports aisle and into everyday drinking occasions. We built this line to target both sides of the bar, hydration by day and cocktail-ready by night,” said Mark Thomas Lynn, Founder and Chief Executive Officer of AMASS. “Four months after launch, the business has reached an approximately $1.4 million annualized revenue run rate, and September revenue through the 28th is already nearly double August’s total.”

“The next phase is about repeat purchases, reaching more accounts in the six markets we already serve, and growing a powder business we sell and ship ourselves,” Lynn continued. “We have the distributor relationships and the digital capability in house. This is about pointing them at one focused opportunity.”

An Everyday Approach to Electrolytes

AMASS Electrolytes brings together sparkling mixers and portable powders designed around taste, convenience and everyday occasions. Its sparkling format serves both as a standalone beverage and a cocktail mixer, while powders expand the brand’s reach into at-home and on-the-go consumption. AMASS expects to further expand its electrolyte business through an established national platform serving approximately 20,000 beverage alcohol accounts, with reach across all 50 states and 606 distinct chain banners reached to date. The Company’s strategy combines introducing AMASS Electrolytes to existing portfolio accounts with pursuing new distribution in grocery, natural and wellness channels.

Next Phase of Growth

AMASS is prioritizing three areas:

  • Expand distribution: Increase penetration within its six current markets and pursue additional retail and distributor opportunities.
  • Build repeat purchases: Support existing accounts and develop consumer awareness around everyday electrolyte occasions.
  • Scale hydration powders online: Grow direct-to-consumer sales through the Company’s in-house digital marketing capabilities.

The powder format also carries a capital efficiency advantage. Powders ship without water or glass, which means lower freight cost, denser pallets and less cash tied up in inventory than ready-to-drink formats.

About AMASS Electrolytes

AMASS Electrolytes are crafted with clean ingredients and designed to support recovery and everyday performance with a blend of essential electrolytes and real Pacific sea salt. The sparkling mixers are consumable as a standalone beverage or as a mixer with alcoholic or non-alcoholic spirits, and the hydration powders extend the line into at-home and on-the-go occasions. The line contains lower calories and sugar versus competitors and is Non-GMO, Gluten-Free, and Vegan. Formulations vary by flavor to deliver the right taste profile for each occasion, and full nutritional information for every AMASS Electrolytes flavor is available at www.amass.com.

About AMASS Brands Group

AMASS Brands Group (Nasdaq: AMSS) is a next-generation beverage platform built around the brands defining how modern consumers drink, and increasingly, how they don’t. The company’s portfolio spans non-alcohol, functional, and alcohol 2.0 categories, with standout brands across each: Good Twin Non-Alcoholic Wine, a top non-alcoholic wine in the U.S. and one of the fastest-growing in the category; AMASS Electrolytes, a functional disruptor redefining the hydration category; and Summer Water Rosé, the zero-sugar, #1-selling domestic rosé priced between $15 and $20 in the U.S., among others across the portfolio. As moderation trends accelerate, AMASS is positioned to benefit structurally rather than reactively, with margin discipline, cohesive brand architecture, and the multi-brand scalability that supports the Company’s long-term brand and platform growth strategy.

Follow AMASS on LinkedIn
Follow AMASS on Instagram

Revenue Run Rate and Unaudited Information
The approximately $1.4 million annualized revenue run rate is calculated by multiplying September 2026 AMASS Electrolytes revenue booked through September 28, 2026 of approximately $116,000 by 12, resulting in $1.392 million. It does not extrapolate additional revenue for the remaining days of September. It is not revenue earned over the preceding 12 months, a full-year forecast or a guarantee of future performance. Revenue figures are unaudited and subject to normal quarter-end adjustments. Monthly revenue may fluctuate due to order timing, distributor inventory purchases, seasonality and other factors. The figures in this release relate to AMASS Electrolytes, not the Company’s total consolidated revenue.

Safe Harbor Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding the Company’s expectations, beliefs, plans, intentions, strategies, prospects, future growth opportunities, anticipated market trends, distribution expansion, consumer demand, and future operating performance. These forward-looking statements include, without limitation, the Company’s statements regarding the anticipated commercial benefits of expanding AMASS Electrolytes through its existing distribution platform and into additional retail channels, anticipated consumer demand and repeat purchases, growth of direct-to-consumer hydration powder sales, and expected freight, inventory and capital efficiency benefits of the powder format. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions, changes in consumer demand, competitive conditions within the beverage industry, the Company’s ability to expand distribution and retail penetration, generate repeat purchases and grow direct-to-consumer sales, supply chain disruptions, freight and inventory costs, the availability of capital to support growth, and the other factors discussed in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in the Company’s SEC filings, which are available at www.sec.gov. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to publicly revise or update these forward-looking statements to reflect events or circumstances that arise after the date hereof, except as required by applicable law.

Investor Relations Contact
KCSA Strategic Communications
Rob Kelly, Vice President
(212) 896-1254
AMASS@KCSA.com

Progress Software Launches ShareFile Enterprise

New ShareFile Enterprise offering helps organizations scale collaboration without scaling manual administration and security work through enterprise identity management, native data loss prevention and AI-driven threat detection.
New ShareFile Enterprise offering helps organizations scale collaboration without scaling manual administration and security work through enterprise identity management, native data loss prevention and AI-driven threat detection.

New ShareFile Enterprise offering helps organizations scale collaboration without scaling manual administration and security work through enterprise identity management, native data loss prevention and AI-driven threat detection

BURLINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Progress Software (Nasdaq: PRGS), an AI infrastructure software leader, today announced Progress® ShareFile® Enterprise, a new offering that helps larger and regulated organizations scale sensitive document collaboration from a single platform with enhanced capabilities that support governance and security. By combining automated access, SOC-connected visibility, native data loss prevention, intelligent risk monitoring and rich investigation context, ShareFile Enterprise gives IT and security teams greater visibility, control and governance over sensitive document workflows, without disrupting the user experience.

The result is a more scalable approach to document collaboration and file sharing that helps organizations reduce administrative burden, strengthen governance and support growth without changing how employees, clients and partners work.

Sensitive document collaboration in many organizations is expanding faster than the controls built to govern it. As organizations grow, more people and workflows interact with sensitive and confidential information. At the same time, IT and security teams often rely on manual provisioning, disconnected monitoring workflows, log exports, user judgment and fragmented investigations of anomalies. Together, these create additional operational overhead as collaboration scales. The challenge is no longer simply securing more files but maintaining consistent control without creating more work, increasing operational costs or slowing down the business.

“What became clear to us is that client collaboration is about much more than where files live,” said Scott Jenkins, Director of Information Technology, Keel Point. “We need the right controls, secure client experiences and workflows to support how we work with clients, families and their advisors. ShareFile gives us that foundation, and Enterprise gives us an opportunity to strengthen it with even greater security, governance and visibility.”

ShareFile Enterprise builds on established, secure ShareFile collaboration capabilities to meet the scale and governance needs of larger organizations, with enhanced access controls and unusual activity detection to help reduce administrative overhead and strengthen security. Native Data Loss Prevention applies consistent policies to sensitive content, AI-driven behavioral analytics helps surface unusual activity quickly and a centralized security experience connects alerts with the context teams need to support more informed investigation and response.

ShareFile Enterprise includes:

  • SCIM provisioning with Microsoft Entra ID: Automates employee provisioning and deactivation to help keep ShareFile access aligned with workforce changes and reduce repetitive access administration.
  • SIEM integration with Splunk and Microsoft Sentinel: Routes supported ShareFile activity and security events into existing SOC monitoring tools, providing ShareFile context where security teams already work and reducing dependence on manual log exports or custom integrations.
  • Native DLP (available as of October 1, 2026): Detects supported sensitive text-based content and allows administrators to apply policies that can alert, restrict external sharing or prevent downloads, moving sensitive-data protection from user reminders to consistent policy enforcement.
  • User and Entity Behavior Analytics (UEBA) (available as of October 1, 2026): Analyzes activity patterns to surface unusual behavior such as abnormal downloads, off-hours activity or atypical access patterns, helping security teams identify activity worth investigating sooner.
  • Centralized security operations experience (available as of October 1, 2026): Brings supported security alerts, user and activity context and investigation paths into one place, helping shorten the distance between seeing an alert, understanding what happened and determining the next appropriate action.

“For most of the last decade, as enterprises’ needs for document collaboration have scaled, they have had to layer manual security and administration work on top of the tools their teams use. With today’s governance and security standards, that model is reaching its limits,” said Loren Jarrett, EVP and General Manager, Digital Experience, Progress Software. “With the new ShareFile Enterprise offering, organizations can gain built-in control as collaboration grows, without scaling manual administration and disconnected processes. That means better outcomes and more time spent supporting the business.”
        
For more information about ShareFile Enterprise, visit https://www.sharefile.com/enterprise.

About Progress Software 
Progress Software (Nasdaq: PRGS) provides the context and control organizations need to reliably extract value from AI—context drawn from an organization’s data, content and workflows, and control over the security, governance and cost of their AI initiatives. Learn how hundreds of thousands of businesses, powering the work of tens of millions of professionals worldwide, realize value from trusted, enterprise-ready AI at www.progress.com.

Progress and ShareFile and certain product names used herein are trademarks or registered trademarks of Progress Software Corporation and/or one of its subsidiaries or affiliates in the U.S. and/or other countries. See Trademarks for appropriate markings. All rights in any other trademarks contained herein are reserved by their respective owners and their inclusion does not imply an endorsement, affiliation or sponsorship as between Progress and the respective owners.

Press Contact:           
Kim Baker
Progress Software        
+1-800-477-6473    
pr@progress.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d31cd9c9-b685-4eb6-b94c-c80a0f9c0fb7

Olathe, KS, Sept. 29, 2026 (GLOBE NEWSWIRE) — Kustom Entertainment, Inc. (NASDAQ: KUST) (the “Company”), a leader in live event production and ticketing technology, today announced a 1-for-10 reverse split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”) and proportional reduction of the number of shares of Common Stock authorized (the “Capital Stock Reduction”). The Company anticipates that the Common Stock will begin trading on the Nasdaq Capital Market (“Nasdaq”) on a split-adjusted basis at the start of trading on October 1, 2026 and will have a new CUSIP number of 25382T705.

The Reverse Stock Split is being implemented to increase the per share trading price of the Company’s Common Stock for the purpose of ensuring a share price high enough to comply with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.

On September 18, 2026, the Company’s board of directors approved a 1-for-10 Reverse Stock Split. The number of outstanding shares of Common Stock prior to the Reverse Stock Split is 6,506,860 and the number of outstanding shares of Common Stock following the Reverse Stock Split is 650,686, subject to adjustment for the rounding up of fractional shares.

The number of authorized shares of Common Stock prior to the Capital Stock Reduction was 13,333,333. The number of authorized shares of Common Stock following the Capital Stock Reduction is 1,333,334. The number of authorized shares of preferred stock is not affected.

Information to Stockholders

Nevada Agency and Transfer Company (“NATCO”), the Company’s transfer agent, will send instructions to stockholders of record who hold stock certificates regarding the exchange of certificates for Common Stock. Stockholders who hold their shares of Common Stock in book-entry form or in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares of Common Stock following the Reverse Stock Split. NATCO may be reached for questions at 775-322-5623.

About Kustom Entertainment, Inc. – Kustom Entertainment, Inc. is a leader in live event production and ticketing technology. The company specializes in large-scale music festivals, including the legendary Country Stampede, and provides end-to-end event management and proprietary ticketing solutions for venues across the United States. The Country Stampede Festival is one of the company’s flagship events, celebrating the best in country music while fostering community and providing a platform for emerging talent. For more information, visit http://www.kustoment.com/

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Reverse Stock Split, Capital Stock Reduction, and references to the live event production business, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned, including, without limitation, risks and uncertainties related to the growth of the live event industry, and there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact Information
Stanton Ross, CEO
Tom Heckman, CFO
Kustom Entertainment, Inc.
Phone: (913) 456-KUST (5878)
Email: info@kustoment.com
Website: www.kustoment.com

Appointment as Senior Strategic Advisor marks the Company’s expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South America

DiTota spent over two decades in neuromodulation at Abbott and Medtronic, two of the largest companies in the field, including responsibility for Abbott’s North America commercial neuromodulation business, a division representing approximately $700 million in business

Nexalin’s Gen-2 SYNC device is already approved in China, Brazil, Oman and Israel; the engagement is intended to build the distribution relationships, go-to-market plan and commercial infrastructure required to convert those approvals into commercial sales

HOUSTON, TX, Sept. 29, 2026 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), developer of non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology, today announced the appointment of Robert DiTota as Senior Strategic Advisor, Global Commercialization, effective September 15, 2026. Mr. DiTota will work directly with Nexalin’s executive management team, and with its Board of Directors as requested, to advise on the Company’s commercial strategy, international distribution and market development plan, go-to-market approach, and the commercial infrastructure and organizational development needed to support distribution of the Company’s neurostimulation platform.

The appointment marks an expansion of focus for Nexalin. Over the past several years the Company has concentrated on building the clinical and regulatory foundation for its DIFS™ platform, including peer-reviewed publication of its Alzheimer’s trial results, completed clinical work in Brazil, an FDA Q-Submission meeting in support of a planned U.S. pilot study in Alzheimer’s disease, and the initiation of the HALO™ Clarity pivotal program in insomnia, which is ongoing. The Company’s Gen-2 SYNC 15 milliamp device has been approved in China, Brazil, Oman and Israel. With that foundation in place, Nexalin is now building the commercial capability to distribute its technology, beginning in those approved markets and extending to the United States and Europe as regulatory milestones are achieved.

The Company is pursuing that opportunity in a market that Grand View Research estimates at approximately $7.0 billion in 2026 and projects will reach $13.9 billion by 2033. Nexalin’s position in that market rests on its clinical record. The Company’s Gen-2 SYNC device was evaluated in a randomized, double-blind, sham-controlled trial that showed statistically significant improvement versus sham on the Mini-Mental State Examination (P = .001) and the Montreal Cognitive Assessment (P = .03), together with treatment-associated changes in functional connectivity observed on MRI, and those results were published in the Journal of Alzheimer’s Disease and in Radiology. The Company believes that combination of controlled clinical data, peer-reviewed publication and regulatory approval in four countries differentiates its DIFS™ platform within non-invasive neurostimulation and provides a foundation for commercial development.

Mr. DiTota has spent more than two decades in neuroscience and medical device sales, including over 20 years in neuromodulation at Medtronic and Abbott. Beginning in 2016 he held a series of increasingly senior commercial roles at Abbott Medical Devices, most recently as Divisional Vice President of Sales for North America Commercial Neuromodulation, where he was responsible for downstream marketing, commercial excellence, sales operations, enterprise accounts, commercial strategy and sales training across a division representing approximately $700 million in business, as well as for the division’s merger and acquisition activity. As Vice President of Sales for North America Movement Disorders, he increased revenue by more than $20 million within his first year in the role. Earlier at Abbott, as Regional Sales Manager for the Northeast, he led a market development effort that opened 60 new implanting centers and grew that business from zero to more than $16 million.

Prior to Abbott, Mr. DiTota spent nine years at Medtronic, Inc., where he supported the Deep Brain Stimulation franchise across the New York metropolitan region and served as a sales and marketing representative on the launch of Medtronic’s Activa platform. He is a named co-author on published research in deep brain stimulation, including work appearing in the Journal of Clinical Neuroscience.

“The clinical and regulatory work of the past several years is what makes this next phase possible,” said Mark White, President and Chief Executive Officer of Nexalin Technology. “We have approvals in four countries and a growing body of published data behind the technology. What we need to build now is the commercial organization that turns that into sales. Rob has spent his career doing exactly that in neuromodulation, at Abbott and at Medtronic,in the United States. He understands how these products reach physicians and patients, how distribution partners are selected and held accountable, and what has to be in place before a launch. We are fortunate to have him working alongside us as we make this transition.”

“Nexalin has established an important clinical and regulatory foundation,” said Robert DiTota. “The company has generated controlled clinical data, published peer-reviewed results, and secured regulatory approvals for its Gen-2 SYNC device in four countries. The commercial opportunity now is to translate that foundation into disciplined market development in approved geographies while continuing to build the evidence, regulatory strategy and infrastructure needed for broader commercialization. That is the work in front of us.”

The Company intends to provide further updates as its commercialization strategy advances.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. Nexalin’s medical devices are non-invasive and undetectable to the human body. Nexalin products are developed to provide relief to those afflicted with mental health issues using frequency based bioelectronic medical technology. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices supports enhanced patient response with a favorable tolerability profile. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). These forward-looking statements relate to future events, future performance, or management’s current expectations, beliefs, assumptions, plans, estimates, intentions, or projections relating to the future, and are not guarantees of future performance. Any statements that are not statements of historical fact, or that refer to expectations, projections, or other characterizations of future events or circumstances (including, without limitation, statements containing the words “believes,” “expects,” “anticipates,” “plans,” “intends,” “will,” “may,” “could,” “should,” “would,” “designed to,” “positioned to,” “potential,” “targeted,” “seeking,” “continues,” “strategy,” “opportunity,” “estimates,” “projects,” “forecasts,” “predicts,” “outlook,” “guidance,” or similar expressions, or the negative of such terms), are forward-looking statements. Forward-looking statements also include the statements contained in the headline and subheadings of this press release and the statements attributed in quotations to the Company’s management and to Mr. DiTota, in each case to the extent they describe plans, objectives or expectations for future operations. Forward-looking statements are based on Nexalin’s current expectations, assumptions, estimates, projections, and beliefs as of the date hereof. These statements are subject to significant risks, uncertainties, and other factors, many of which are beyond the Company’s control, that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company’s expansion from a clinical development focus toward commercialization and distribution of its products; the anticipated scope, contribution and results of Mr. DiTota’s engagement as Senior Strategic Advisor, Global Commercialization, and the Company’s expectation that his experience will support the development of the Company’s commercial strategy, distribution relationships, go-to-market planning and commercial infrastructure; the Company’s ability to convert existing international regulatory approvals into commercial sales; the Company’s plans to pursue commercialization in the United States, Europe and other markets where regulatory approval has not yet been obtained; estimates of market size, market composition and market growth prepared by third parties, which are based on assumptions that may prove inaccurate and which do not represent the Company’s addressable market or any expectation of the Company’s future revenue; the design, enrollment, timing, progress, results and potential outcomes of the Company’s clinical development programs, including its planned U.S. pilot study in Alzheimer’s disease and the HALO™ Clarity pivotal study in insomnia; the mechanism of action, depth of penetration, safety profile and differentiation of Nexalin’s DIFS™ platform, including the Company’s belief that the deeper-penetrating waveform in its next-generation devices supports enhanced patient response with a favorable tolerability profile; the Company’s belief that its controlled clinical data, peer-reviewed publications and existing regulatory approvals differentiate its DIFS™ platform and provide a foundation for commercial development; management’s expectations regarding future regulatory submissions, clearances and approvals; and the Company’s strategic plans, business prospects, capital needs, and ability to continue as a going concern.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the Company’s control. Such risks include, but are not limited to: the risk that the Company’s expansion toward commercialization may be delayed, may require substantially more capital, time or personnel than anticipated, or may not result in commercial sales or revenue; the risk that the engagement of a strategic advisor will not produce the commercial capabilities, distribution relationships or results the Company anticipates; the risk that the revenue growth and market development results attributed to Mr. DiTota in his prior roles at Abbott and Medtronic, which were achieved at substantially larger companies with established products, sales organizations and reimbursement, are not indicative of results the Company may achieve; the fact that Mr. DiTota is engaged as a non-exclusive independent consultant on a part-time basis, is not an officer or employee of the Company, and may terminate his engagement on thirty days’ notice; the Company’s limited commercial operations, limited revenue to date, and lack of an established sales and distribution organization; the risk that regulatory approvals obtained in international markets will not result in commercial sales; the risk that the approvals obtained in China, Brazil, Oman and Israel are limited in scope or indication, are subject to conditions, or may be modified, suspended or withdrawn; the risk that the results of the randomized, double-blind, sham-controlled trial described in this press release, including the Mini-Mental State Examination and Montreal Cognitive Assessment endpoints and the MRI functional connectivity findings, will not be replicated in larger or later-stage studies, will not be accepted by the FDA or other regulators as adequate support for marketing authorization, and may not translate into physician adoption, reimbursement or commercial demand; the Company’s dependence on third-party distributors and partners in international markets, and the risk that such arrangements may not be executed, may not be performed, or may not generate the volumes or revenue contemplated; the risk that third-party market estimates cited herein are inaccurate, measure a market broader than the products the Company offers, or that the Company will capture no meaningful share of any such market; the ability to obtain regulatory clearance or approval from the FDA or other regulatory bodies, including with respect to the Company’s planned U.S. pilot study in Alzheimer’s disease and the HALO™ Clarity pivotal program in insomnia, and the fact that the Company’s products are not currently approved for commercial sale in the United States or Europe; uncertainties regarding the design, enrollment, execution, timing, results and completion of clinical trials; the potential for adverse events, safety concerns, or product performance issues; market acceptance of, and reimbursement for, the Company’s products; the Company’s ability to protect and enforce its intellectual property rights; competition from existing and new treatment alternatives, including from substantially larger and better capitalized companies, including Abbott and Medtronic; the Company’s reliance on third-party manufacturers and suppliers; the Company’s ability to maintain compliance with the continued listing requirements of The Nasdaq Stock Market; the Company’s ability to secure adequate funding on acceptable terms to complete its planned clinical, regulatory and commercial programs; and general economic, political, regulatory and market conditions. Additional risks and uncertainties that could cause actual results to differ materially are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, and in the Company’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings the Company makes from time to time with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these filings are available free of charge on the SEC’s website at www.sec.gov and on the Company’s investor relations website. New risk factors emerge from time to time, and it is not possible for the Company to predict all such risk factors or to assess the impact of all such risk factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

All forward-looking statements in this press release are qualified in their entirety by this cautionary statement and the risk factors and other cautionary statements set forth in the Company’s SEC filings referenced above, and speak only as of the date they are made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise, after the date of this press release.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.